Bristol-Myers Squibb Foundation awards $1.6 million in grants

Bristol-Myers SquibbThe Bristol-Myers Squibb Foundation announced $1.6 million in grants to four health care institutions in India that will help improve diabetes education, prevention and care and increase health care worker capacity in rural and tribal areas and among the urban poor.

The prevalence of diabetes in India has grown roughly four-fold since the early 1970s - from about 2 percent of the population in 1972 to 8.3 percent today - due to factors ranging from genetic predisposition to lifestyle and dietary changes. The International Diabetes Foundation (IDF) reports that 61.26 million people in India are diagnosed with type 2 diabetes, ranking India second only to China in total cases and third behind the United States (10.9 percent) and China (9.3 percent) in terms of prevalence. By 2030, India will have 101.2 million people with type 2 diabetes, IDF projects.

"Stemming the rising tide of type 2 diabetes in India will require a concerted and sustained effort at the community level to ensure adults have access to the education, preventive measures and care they need to effectively self-manage their disease," said John Damonti, president, Bristol-Myers Squibb Foundation. "The grants we are making today through our Together on Diabetes™ initiative will test new ideas about how diabetes control efforts can be best designed and implemented to help adults in a variety of settings."

The Foundation has employed a similar capacity-building approach with its 10-year-old Delivering Hope™ initiative to address hepatitis B and C in Asia, and its ongoing work to address unmet medical needs, reduce health disparities and build community health care capacity was recognized in late July by CMO Asia with an Asia's Best CSR Practices Award in the Concern for Health category.

The following organizations will receive Together on Diabetes™ grants:

  • Mamta Health Institute for Mother and Child, a national organization based in New Delhi and operating in 14 Indian states, will receive US $706,995 over three years to pilot a study to determine the feasibility of involving India’s lay community health workers (Accredited Social Health Activists) and integrating various systems of medicine including modern and AYUSH, to prevent and control non-communicable diseases, especially type 2 diabetes.
  • All India Institute of Diabetes and Research in Naranpura and Swasthya Diabetes Hospital in Ahmedabad will receive US $465,685 over two years to develop and test a three-setting model to improve access to diabetes education, prevention and care for the poor in rural, tribal and urban settings.
  • Sanjivani Health and Relief Committee in Ahmedabad will receive US $426,374 over four years to conduct a household-by-household study in 348 villages to identify type 2 diabetes and ensure early diagnosis of undetected diabetes among those with pre-diabetes or at high risk of developing diabetes. The study also will determine the prevalence of type 2 diabetes and related complications among the rural poor.

About Together on Diabetes™
Together on Diabetes™ brings together some of the world's most respected and influential health care organizations and academic institutions to develop effective, comprehensive solutions that integrate public health, health care services and supportive community supportive services to improve health outcomes and reduce disease burden.

Since its launch in November 2010, Together on Diabetes™ has awarded $32.57 million in grants to 17 organizations working in 23 states and the District of Columbia in the United States, $1.23 million to two organizations in China and $1.6 million to four organizations in India. The total commitment is $115 million through 2014.

About the Bristol-Myers Squibb Foundation
The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes around the world for patients disproportionately affected by serious diseases.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...

Pfizer and BioNTech choose lead mRNA vaccine candi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a singl...